Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iPfSPZ
- Development stage
- Preclinical
- Lead developer
- Sanaria
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
iPfSPZ (in vitro produced Plasmodium falciparum sporozoites) is a whole-parasite malaria vaccine platform developed by Sanaria. Unlike traditional PfSPZ vaccines which rely on aseptic mosquitoes for production (mPfSPZ), iPfSPZ are mass-produced in vitro using bioreactors. This mosquito-free manufacturing process is designed to significantly increase production efficiency, lower cost of goods by up to 90%, and facilitate large-scale manufacture for mass vaccination programs. iPfSPZ have been shown to successfully invade human hepatocytes and develop into late liver-stage schizonts, demonstrating comparable infectivity and immunogenicity to mosquito-derived sporozoites.
- Other names
- in vitro produced PfSPZin vitro produced Plasmodium falciparum sporozoites
Beyond the preview
Go deeper on iPfSPZ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iPfSPZ.